CXCL12 AND VEGF SYNERGISTICALLY INDUCE NEOANGIOGENESIS IN HUMAN OVARIAN CANCERS

CXCL12 和 VEGF 协同诱导人类卵巢癌新血管生成

• 批准号: 7562354
• 负责人: I KRYCZEK
• 金额: $ 3.04万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562354
• 关键词: Apoptosis; Biological Assay; CXC Chemokines; CXCL12 gene; CXCR4 gene; Computer Retrieval of Information on Scientific Projects Database; Fibroblast Growth Factor; Funding; Grant; Human; Hypoxia; Institution; Liquid substance; Malignant Neoplasms; Malignant neoplasm of ovary; Mediating; Ovarian Carcinoma; Pathologic; Pathway interactions; Patients; Production; Research; Research Personnel; Resources; Serum; Signal Transduction; Source; Starvation; Tumor Angiogenesis; United States National Institutes of Health; Vascular Endothelial Cell; angiogenesis; antiangiogenesis therapy; base; cell motility; in vivo; malignant ascites; matrigel; migration; neovascularization; novel; outcome forecast; ovarian neoplasm; receptor; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Ovarian carcinomas have a poor prognosis, often associated with multifocal i.p. dissemination accompanied by intense neovascularization. To examine tumor angiogenesis in the tumor microenvironment, we studied malignant ascites and tumors of patients with untreated ovarian carcinoma. We observed that malignant ascites fluid induced potent in vivo neovascularization in Matrigel assay. We detected a sizeable amount of vascular endothelial cell growth factor (VEGF) in malignant ascites. However, pathologic concentration of VEGF is insufficient to induce in vivo angiogenesis. We show that ovarian tumors strongly express CXC chemokine stromal-derived factor (SDF-1/CXCL12). High concentration of CXCL12, but not the pathologic concentration of CXC12 induces in vivo angiogenesis. Strikingly, pathologic concentrations of VEGF and CXCL12 efficiently and synergistically induce in vivo angiogenesis. Migration, expansion, and survival of vascular endothelial cells (VEC) form the essential functional network of angiogenesis. We further provide a mechanistic basis for explaining the interaction between CXCL12 and VEGF. We show that VEGF up-regulates the receptor for CXCL12, CXCR4 expression on VECs, and synergizes CXCL12-mediated VEC migration. CXCL12 synergizes VEGF-mediated VEC expansion and synergistically protects VECs from sera starvation-induced apoptosis with VEGF. Finally, we show that hypoxia synchronously induces tumor CXCL12 and VEGF production. Therefore, hypoxia triggered tumor CXCL12 and VEGF form a synergistic angiogenic axis in vivo. Hypoxia-induced signals would be the important factor for initiating and maintaining an active synergistic angiogeneic pathway mediated by CXCL12 and VEGF. Thus, interrupting this synergistic axis, rather than VEGF alone, will be a novel efficient antiangiogenesis strategy to treat cancer.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 卵巢癌预后差，常伴有多灶性腹膜内播散伴强烈的新生血管形成。 为了检测肿瘤微环境中的肿瘤血管生成，我们研究了未经治疗的卵巢癌患者的恶性腹水和肿瘤。 我们观察到恶性腹水在Matrigel测定中诱导了有效的体内新生血管。 我们在恶性腹水中检测到相当数量的血管内皮细胞生长因子（VEGF）。 然而，VEGF的病理浓度不足以诱导体内血管生成。 我们发现卵巢肿瘤强烈表达CXC趋化因子基质衍生因子（SDF-1/CXCL 12）。 高浓度的CXCL 12而非病理浓度的CXC 12诱导体内血管生成。 引人注目的是，病理浓度的VEGF和CXCL 12有效地和协同地诱导体内血管生成。 血管内皮细胞（VEC）的迁移、扩增和存活构成了血管生成的基本功能网络。 我们进一步为解释CXCL 12和VEGF之间的相互作用提供了机制基础。 我们发现，VEGF上调CXCL 12受体，CXCR 4在血管内皮细胞上的表达，并协同CXCL 12介导的血管内皮细胞迁移。 CXCL 12协同VEGF介导的VEC扩增，并协同VEGF保护VEC免受血清饥饿诱导的凋亡。 最后，我们发现，缺氧同步诱导肿瘤CXCL 12和VEGF的生产。 因此，缺氧触发的肿瘤CXCL 12和VEGF在体内形成协同的血管生成轴。 缺氧诱导的信号可能是启动和维持CXCL 12和VEGF介导的积极协同血管生成途径的重要因素。 因此，中断这种协同轴，而不是单独的VEGF，将是一种新的有效的抗血管生成的策略来治疗癌症。